SENP1 and cancer: Sorafenib, a first-line multikinase inhibitor approved for advanced HCC, was shown to modestly prolong median survival by 3–5 months.[42], [43], [44] SENP1 was implicated in cancer progression and may contribute to sorafenib resistance via its regulation of oncogenic proteins such as PIN1.